FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021442034> ?p ?o ?g. }

• W2021442034 endingPage "260" @default.
• W2021442034 startingPage "243" @default.
• W2021442034 abstract "Non-albicans Candida (NAC) species cause 35-65% of all candidaemias in the general patient population. They occur more frequently in cancer patients, mainly in those with haematological malignancies and bone marrow transplant (BMT) recipients (40-70%), but are less common among intensive care unit (ITU) and surgical patients (35-55%), children (1-35%) or HIV-positive patients (0-33%). The proportion of NAC species among Candida species is increasing: over the two decades to 1990, NAC represented 10-40% of all candidaemias. In contrast, in 1991-1998, they represented 35-65% of all candidaemias. The most common NAC species are C. parapsilosis (20-40% of all Candida species), C. tropicalis (10-30%), C. krusei (10-35%) and C. glabrata (5-40%). Although these four are the most common, at least two other species are emerging: C. lusitaniae causing 2-8% of infections, and C. guilliermondii causing 1-5%. Other NAC species, such as C. rugosa, C. kefyr, C. stellatoidea, C. norvegensis and C. famata are rare, accounting for less than 1% of fungaemias in man. In terms of virulence and pathogenicity, some NAC species appear to be of lower virulence in animal models, yet behave with equal or greater virulence in man, when comparison is made with C. albicans. Mortality due to NAC species is similar to C. albicans, ranging from 15% to 35%. However, there are differences in both overall and attributable mortality among species: the lowest mortality is associated with C. parapsilosis, the highest with C. tropicalis and C. glabrata (40-70%). Other NAC species including C. krusei are associated with similar overall mortality to C. albicans (20-40%). Mortality in NAC species appears to be highest in ITU and surgical patients, and somewhat lower in cancer patients, children and HIV-positive patients. There is no difference between overall and attributable mortality, with the exception of C. glabrata which tends to infect immunocompromised individuals. While the crude mortality is low, attributable mortality (fungaemia-associated mortality) is higher than with C. albicans. There are several specific risk factors for particular NAC species: C. parapsilosis is related to foreign body insertion, neonates and hyperalimentation; C. krusei to azole prophylaxis and along with C. tropicalis to neutropenia and BMT; C. glabrata to azole prophylaxis, surgery and urinary or vascular catheters; C. lusitaniae and C. guilliermondii to previous polyene (amphotericin B or nystatin) use; and C. rugosa to burns. Antifungal susceptibility varies significantly in contrast to C. albicans: some NAC species are inherently or secondarily resistant to fluconazole; for example, 75% of C. krusei isolates, 35% of C. glabrata, 10-25% of C. tropicalis and C. lusitaniae. Amphotericin B resistance is also seen in a small proportion: 5-20% of C. lusitaniae and C. rugosa, 10-15% of C. krusei and 5-10% of C. guilliermondii. Other NAC species are akin to C. albicans-susceptible to both azoles and polyenes (C. parapsilosis, the majority of C. guilliermondii strains and C. tropicalis). Therefore, 'species directed' therapy should be administered for fungaemia according to the species identified-amphotericin B for C. krusei and C. glabrata, fluconazole for other species, including polyene-resistant or tolerant Candida species (C. lusitaniae, C. guilliermondii). In vitro susceptibility testing should be performed for most species of NAC in addition to removal of any foreign body to optimize management." @default.
• W2021442034 created "2016-06-24" @default.
• W2021442034 creator A5042756197 @default.
• W2021442034 creator A5060185105 @default.
• W2021442034 date "2002-04-01" @default.
• W2021442034 modified "2023-10-18" @default.
• W2021442034 title "Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance" @default.
• W2021442034 cites W1541898536 @default.
• W2021442034 cites W1605741356 @default.
• W2021442034 cites W1834964532 @default.
• W2021442034 cites W18351075 @default.
• W2021442034 cites W1874406936 @default.
• W2021442034 cites W1958103205 @default.
• W2021442034 cites W1963736439 @default.
• W2021442034 cites W196899653 @default.
• W2021442034 cites W1969010760 @default.
• W2021442034 cites W1973697574 @default.
• W2021442034 cites W1973802801 @default.
• W2021442034 cites W1975408222 @default.
• W2021442034 cites W1976436140 @default.
• W2021442034 cites W1989728928 @default.
• W2021442034 cites W1991882850 @default.
• W2021442034 cites W1993685063 @default.
• W2021442034 cites W1999528273 @default.
• W2021442034 cites W2001262692 @default.
• W2021442034 cites W2010098496 @default.
• W2021442034 cites W2013907403 @default.
• W2021442034 cites W2017817339 @default.
• W2021442034 cites W2026714613 @default.
• W2021442034 cites W2027859345 @default.
• W2021442034 cites W2029881815 @default.
• W2021442034 cites W2035306892 @default.
• W2021442034 cites W2040987862 @default.
• W2021442034 cites W2046424277 @default.
• W2021442034 cites W2047133769 @default.
• W2021442034 cites W2053859179 @default.
• W2021442034 cites W2062611574 @default.
• W2021442034 cites W2067710509 @default.
• W2021442034 cites W2074890764 @default.
• W2021442034 cites W2076689151 @default.
• W2021442034 cites W2078639325 @default.
• W2021442034 cites W2082996726 @default.
• W2021442034 cites W2091936255 @default.
• W2021442034 cites W2092327393 @default.
• W2021442034 cites W2093801207 @default.
• W2021442034 cites W2095696028 @default.
• W2021442034 cites W2096480959 @default.
• W2021442034 cites W2098790553 @default.
• W2021442034 cites W2099236698 @default.
• W2021442034 cites W2099906391 @default.
• W2021442034 cites W2105896831 @default.
• W2021442034 cites W2106715375 @default.
• W2021442034 cites W2108439465 @default.
• W2021442034 cites W2111240123 @default.
• W2021442034 cites W2120148678 @default.
• W2021442034 cites W2120479782 @default.
• W2021442034 cites W2124378855 @default.
• W2021442034 cites W2124818206 @default.
• W2021442034 cites W2125476190 @default.
• W2021442034 cites W2126246398 @default.
• W2021442034 cites W2126536749 @default.
• W2021442034 cites W2131811964 @default.
• W2021442034 cites W2132633210 @default.
• W2021442034 cites W2140701924 @default.
• W2021442034 cites W2145295807 @default.
• W2021442034 cites W2146628648 @default.
• W2021442034 cites W2147381690 @default.
• W2021442034 cites W2149716740 @default.
• W2021442034 cites W2151900091 @default.
• W2021442034 cites W2152107402 @default.
• W2021442034 cites W2156061147 @default.
• W2021442034 cites W2162952462 @default.
• W2021442034 cites W2169653839 @default.
• W2021442034 cites W2223077454 @default.
• W2021442034 cites W2313875412 @default.
• W2021442034 cites W2314166559 @default.
• W2021442034 cites W2327998360 @default.
• W2021442034 cites W2328377514 @default.
• W2021442034 cites W2332111302 @default.
• W2021442034 cites W2333499420 @default.
• W2021442034 cites W2334491615 @default.
• W2021442034 cites W2339375844 @default.
• W2021442034 cites W2341266869 @default.
• W2021442034 cites W2403102906 @default.
• W2021442034 cites W2409815848 @default.
• W2021442034 cites W2412125464 @default.
• W2021442034 doi "https://doi.org/10.1053/jhin.2001.1151" @default.
• W2021442034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12014897" @default.
• W2021442034 hasPublicationYear "2002" @default.
• W2021442034 type Work @default.
• W2021442034 sameAs 2021442034 @default.
• W2021442034 citedByCount "649" @default.
• W2021442034 countsByYear W20214420342012 @default.
• W2021442034 countsByYear W20214420342013 @default.
• W2021442034 countsByYear W20214420342014 @default.
• W2021442034 countsByYear W20214420342015 @default.
• W2021442034 countsByYear W20214420342016 @default.
• W2021442034 countsByYear W20214420342017 @default.

• next